ArticleInternational journal of molecular sciences2018
Antagonism of Transient Receptor Potential Ankyrin Type-1 Channels as a Potential Target for the Treatment of Trigeminal Neuropathic Pain: Study in an Animal Model.
Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Trigeminal neuralgia and genetics: A systematic review.Molecular painPooled it
- Effectiveness and Tolerability of Topical Amitriptyline 10% Plus Lidocaine 2% Gel in Adults With Post-Traumatic Trigeminal Neuropathic Pain: A Real-World Evidence Study.Journal of oral rehabilitation · 2026Observational
- Emerging Pharmacological Strategies for Trigeminal Neuralgia.CNS drugs · 2026Review
- Insights into the Involvement of TRPA1 Channels in the Neuro-Inflammatory Machinery of Trigeminal Neuralgia.Molecules (Basel, Switzerland) · 2025Article
- Cyclodextrin derivatives decrease Transient Receptor Potential vanilloid 1 and Ankyrin 1 ion channel activation via altering the surrounding membrane microenvironment by cholesterol depletion.Frontiers in cell and developmental biology · 2024Article
- URB937 Prevents the Development of Mechanical Allodynia in Male Rats with Trigeminal Neuralgia.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Migraine Treatment: Towards New Pharmacological Targets.International journal of molecular sciences · 2023Review
- Targeted Therapy for Orofacial Pain: A Novel Perspective for Precision Medicine.Journal of personalized medicine · 2023Review
- Neuronal and non-neuronal TRPA1 as therapeutic targets for pain and headache relief.Temperature (Austin, Tex.) · 2023Review
- Modulation of Glia Activation by TRPA1 Antagonism in Preclinical Models of Migraine.International journal of molecular sciences · 2022Article
- Lipoyl-Based Antagonists of Transient Receptor Potential Cation A (TRPA1) Downregulate Osteosarcoma Cell Migration and Expression of Pro-Inflammatory Cytokines.ACS pharmacology & translational science · 2022Article
- A novel implantable device for sensory and affective assessment of orofacial pain in rats.Frontiers in veterinary science · 2022Article
- Potential Molecular Targets for Treating Neuropathic Orofacial Pain Based on Current Findings in Animal Models.International journal of molecular sciences · 2021Review
- Chemogenetic activation of central gastrin-releasing peptide-expressing neurons elicits itch-related scratching behavior in male and female mice.Pharmacology research & perspectives · 2021Article
- Ion Channels of Nociception.International journal of molecular sciences · 2020Article
- Neuropeptide Y tonically inhibits an NMDAR➔AC1➔TRPA1/TRPV1 mechanism of the affective dimension of chronic neuropathic pain.Neuropeptides · 2020Article
- Niosomal Formulation of a Lipoyl-Carnosine Derivative Targeting TRPA1 Channels in Brain.Pharmaceutics · 2019Article
- Pathological Mechanisms and Therapeutic Targets for Trigeminal Neuropathic Pain.Medicines (Basel, Switzerland) · 2019Review
- Is TRPA1International journal of molecular sciences · 2019Review
- Animal models - Mimicking the pain of trigeminal neuralgia.Indian journal of pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Transient receptor potential ankyrin type-1 (TRPA1) channels are known to actively participate in different pain conditions, including trigeminal neuropathic pain, whose clinical treatment is still unsatisfactory. The aim of this study was to evaluate the involvement of TRPA1 channels by means of the antagonist ADM_12 in trigeminal neuropathic pain, in order to identify possible therapeutic targets. A single treatment of ADM_12 in rats 4 weeks after the chronic constriction injury of the infraorbital nerve (IoN-CCI) significantly reduced the mechanical allodynia induced in the IoN-CCI rats. Additionally, ADM_12 was able to abolish the increased levels of TRPA1, calcitonin gene-related peptide (CGRP), substance P (SP), and cytokines gene expression in trigeminal ganglia, cervical spinal cord, and medulla induced in the IoN-CCI rats. By contrast, no significant differences between groups were seen as regards CGRP and SP protein expression in the pars caudalis of the spinal nucleus of the trigeminal nerve. ADM_12 also reduced TRP vanilloid type-1 (TRPV1) gene expression in the same areas after IoN-CCI. Our findings show the involvement of both TRPA1 and TRPV1 channels in trigeminal neuropathic pain, and in particular, in trigeminal mechanical allodynia. Furthermore, they provide grounds for the use of ADM_12 in the treatment of trigeminal neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.